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It has been appreciated for some time 
that the expression of TGF-β by some 
tumors or their surrounding tissue stroma 
can bring about dual undesired effects on 
tumor progression and metastasis. First, 
tumors that escape the growth-regula-
tory effects of TGF-β as a result of their 
inherent genetic instability have effec-
tively uncoupled an important physiologi-
cal “brake” on their own growth, resulting 
in greater local tumor invasiveness, 
an increased likelihood of metastasis, 
and the production of even more TGF-β 
(Figure 1). At some critical point, signifi-
cant immune suppression may also occur 
as a result of the negative effects of TGF-β 
on T cell activation (Gorelik and Flavell, 
2000) and a reduction of antigen presen-
tation. For immunogenic tumors secreting 
TGF-β, rendering the tumor-reactive CD8+ 
T cells refractory to its inhibitory effects 
may be sufficient to induce tumor rejec-
tion (Gorelik and Flavell, 2001). Indeed, 
adoptively transferring such “disinhibited” 
CD8+ T cells to syngeneic tumor-bearing 
hosts also resulted in tumor regression. 
Therefore, blockade of these two major 
adverse effects of TGF-β might potential-
ly provide an opportunity for therapeutic 
intervention for certain types of cancer.
In the current issue of Cancer Cell, 
Drs. Dori Thomas and Joan Massagué 
from the Sloan-Kettering Cancer Center 
in New York have defined some of the 
critical gene targets and begun to dis-
sect the signaling pathways activated by 
TGF-β to adversely affect CTL effector 
mechanisms (Thomas and Massagué, 
2005). Using EL4 thymoma cells that 
constitutively secrete TGF-β, these 
investigators showed that co-overexpres-
sion of a molecular “trap” comprising the 
extracellular domain of the TGF-β type 
II receptor by the tumor cells resulted in 
survival of the majority of mice inocu-
lated with the tumor. Importantly, in this 
model, neither CD8+ T cell numbers 
nor their activation status appeared to 
be adversely affected by TGF-β. Gene 
microarray analysis of CD8+ T cells acti-
vated in vitro through crosslinking their T 
cell receptors and CD28 in the presence 
or absence of TGF-β revealed around 
100 genes whose expression level was 
significantly (2- to 6-fold) influenced by 
TGF-β exposure. Among these were the 
genes encoding five key effector proteins 
of CTLs: perforin, granzymes A and B, 
Fas ligand, and interferon-γ, all of which 
were profoundly suppressed, resulting in 
a marked diminution of protein produc-
tion. Perforin (a pore-forming protein) and 
granzymes A and B (serine proteases) 
are copackaged and released from CTLs 
by granule exocytosis following their 
conjugation of tumor cells. Granzymes 
induce various apoptotic programs in 
target cells, some dependent upon, and 
others that do not require, caspase acti-
vation. But these activities are dependent 
on perforin, whose membranolytic prop-
erties are critical for granzymes to access 
and cleave their substrates (Trapani and 
Smyth, 2002). The Fas ligand can also 
induce tumor cell death by engaging 
its cognate death receptor (Fas) on the 
tumor cell, while the pleiotropic effects 
of interferon-γ include potently enhanc-
ing MHC antigen expression on both the 
tumor and local antigen-presenting cells, 
rendering the tumor more visible to the 
immune system.
Thomas and Massagué went on to 
show that the genes encoding the major 
constituents of CTL effector mechanisms 
are targeted directly by TGF-β through the 
Smad signaling pathway. For instance, a 
short sequence within the granzyme B 
gene promoter proved to be the binding 
site of Smad partners ATF1 and CREB 
(which were induced by TGF-β despite 
cycloheximide treatment), as confirmed 
by chromatin immunoprecipitation (ChIP) 
analysis in primary T cells. Similar ChIP 
analysis showed inducible binding of 
ATF1 and Smad 2/3 (but not CREB) to 
the interferon-γ promoter in response to 
TGF-β. The inhibition of granzyme B 
expression by TGF-β was far less pro-
nounced when the levels of ATF1 or 
CREB were specifically knocked down 
using siRNA oligonucleotides. IL-2 also 
largely restored granzyme B and interfer-
on-γ expression in TGF-β-treated T cells, 
whereas IL-15 (which can also induce 
CD8+ T cell proliferation and differentia-
tion) did not. Finally, the authors used an 
EL4 variant expressing the model antigen 
OVA to demonstrate that neutralization of 
TGF-β in vivo both increased the numbers 
of CD8+ CTL capable of detecting the OVA 
peptide SIINFEKL and augmented their 
expression of perforin, granzymes A and 
B, and interferon-γ. Surprisingly, Fas ligand 
expression was not restored, consistent 
with the recognized role for this molecule 
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When a cancer escapes the growth-inhibitory effects of TGF-β secreted by cancer cells themselves or by cells in the local 
stroma, a further adverse outcome for the host is the associated TGF-β-induced suppression of anticancer T cell immunity. 
In addition to the previously described dampening of T cell activation and proliferation, TGF-β markedly and directly sup-
presses the transcription of genes encoding multiple key proteins of the “cytotoxic program” of CD8+ CTL, such as perforin 
and granzymes, cytotoxins that act through the granule exocytosis pathway. The findings described below suggest that TGF-β 
and its signaling pathways will be major targets for novel cancer therapeutics.
Figure 1. Dual adverse effects of tgF-β 
 secretion by tumor cells
the selection of tumor variants resistant to the 
normal growth-regulatory activities of tgF-β 
results in unchecked growth, metastasis, and 
further tgF-β production at the tumor site. the 
cytokine also has marked immunosuppressive 
effects, among them the severe downregula-
tion of ctl effector molecules perforin, gran-
zymes A and b, interferon-γ, and Fas ligand. 
For immunogenic tumors, the abrogation of 
an effective ctl response further enhances 
tumor growth and spread. strategies that 
inhibit tgF-β may therefore potentially play 
a valuable role in the therapy of some can-
cers. green and red arrows indicate positive 
or negative effects, respectively.
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in homeostasis of T cells, rather than a 
prominent role in tumor cell killing.
The findings of Thomas and 
Massagué are significant, as they both 
provide an additional rationale explaining 
the potent tumor-promoting properties of 
TGF-β and define a molecular framework 
to explain how certain T cell effector mol-
ecules known to protect against carcino-
genesis (at least in mice) are inhibited 
by the same cytokine. At least two of the 
effector molecules identified by Thomas 
and Massagué as important targets of 
TGF-β, perforin and interferon-γ, have 
been shown independently to be critical 
for failed immune surveillance of primary 
lymphoid (Smyth et al., 2000; Street et 
al., 2001) and nonlymphoid (Shankaran 
et al., 2001) malignancies in mice, pro-
tecting against both spontaneous and 
carcinogen-induced neoplasia while also 
reducing the metastatic burden associat-
ed with several transplantable tumor cell 
lines. By contrast, mice and humans lack-
ing a functional Fas ligand/Fas pathway 
develop B/T cell lymphoproliferation and 
antibody-induced autoimmunity, suggest-
ing a crucial role for this death pathway 
in lymphoid homeostasis, activation-
induced lymphocyte death, and deletion 
of autoreactive lymphocytes. Unlike per-
forin, a critical role for either granzyme 
A or granzyme B in tumor rejection 
remains controversial. Mice deficient in 
both granzymes have not been reported 
to be particularly tumor-prone as they 
age, but are exquisitely susceptible to the 
viral pathogen ectromelia. Interestingly, 
whereas primary B cell lymphomas that 
arise spontaneously in perforin-deficient 
mice are easily transplantable into syn-
geneic perforin-deficient animals, these 
tumors are uniformly rejected by per-
forin-competent animals that lack both 
granzymes A and B (Smyth et al., 2003). 
In humans, the evidence for a causative 
role of perforin/granzyme dysfunction 
in neoplasia is far less well developed. 
Perforin-deficient children present in 
infancy with life-threatening hemophago-
cytosis in the bone marrow and liver and 
spleen enlargement due to infiltration of 
those organs with activated T cells and 
antigen-presenting cells, and gener-
ally do not survive to adulthood unless 
their cytotoxic capacity is restored by 
bone marrow transplantation (Stepp et 
al., 1999). While a recent report linked 
a perforin allele (Ala91Val) that has 
moderately reduced cytotoxic function 
(Voskoboinik et al., 2005) with childhood 
acute leukemia (Santoro et al., 2005), the 
functional significance of these findings 
requires further clarification, as several 
of the individuals identified possessed 
only a single copy of the defective allele. 
The tools for studying the molecular and 
cellular functions of perforin in humans 
are only beginning to become available 
(Voskoboinik et al., 2004), and the next 
several years may provide important 
insights into perforin and granzyme dys-
functions in a variety of diseases.
By identifying key molecules of the 
“cytotoxicity program” of CD8+ T cells as 
important targets of suppression by TGF-
β, and beginning to unravel the signaling 
pathways responsible for this inhibition, 
the studies of Thomas and Massagué 
have provided a further impetus to efforts 
aimed at developing cancer therapeutics 
based on inhibiting TGF-β signaling.
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